Published in J Virol on April 01, 2001
Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J Virol (2003) 1.42
RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (2006) 1.17
Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter. J Virol (2005) 1.15
Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol (2006) 1.10
Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol (2002) 1.08
The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells. Retrovirology (2004) 1.02
The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol (2004) 1.01
EBNA2 and activated Notch induce expression of BATF. J Virol (2003) 1.00
Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol (2009) 0.98
Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol (2013) 0.89
Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas. J Biol Chem (2012) 0.89
Mitosis-specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 suppresses its function. J Virol (2004) 0.87
Relationship between Epstein-Barr virus-encoded proteins with cell proliferation, apoptosis, and apoptosis-related proteins in gastric carcinoma. World J Gastroenterol (2005) 0.87
The ITAM in Nef influences acute pathogenesis of AIDS-inducing simian immunodeficiency viruses SIVsm and SIVagm without altering kinetics or extent of viremia. J Virol (2002) 0.85
Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res (2014) 0.84
Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol (2010) 0.82
Cellular transcripts regulated during infections with Highly Pathogenic H5N1 Avian Influenza virus in 3 host systems. Virol J (2011) 0.79
Inhibition of germinal centre apoptotic programmes by epstein-barr virus. Adv Hematol (2011) 0.78
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A (2000) 6.30
Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev (1997) 5.49
Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol Cell Biol (1990) 5.08
Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. Mol Cell Biol (1986) 5.07
Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science (1994) 4.87
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol (1985) 4.76
Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J (1997) 4.17
Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J (1999) 3.41
EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 2.79
The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J (1993) 2.74
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer (2000) 2.59
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol (1995) 2.36
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 2.17
Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J Virol (1991) 2.16
The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol (1999) 1.81
The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol (1995) 1.79
The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A (1995) 1.68
Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol (1997) 1.64
Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol (1996) 1.64
Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J (1996) 1.53
Retracted Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci U S A (1999) 1.52
Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene (2000) 1.36
An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol (1998) 1.35
Epstein-Barr virus immortalizing genes. Trends Microbiol (1995) 1.35
Interaction of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) with HS1-associated protein X-1: implication of cytoplasmic function of EBNA-LP. J Virol (2000) 1.28
Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A (1994) 1.28
Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem (1996) 1.24
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J Exp Med (1997) 1.23
BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene (1998) 1.20
Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J Virol (2000) 1.16
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol (1995) 1.12
Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol (2000) 1.11
Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene (1996) 1.11
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med (1993) 1.08
The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res (1995) 1.06
Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol (1999) 1.04
Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol (1997) 1.01
Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends Microbiol (1998) 0.97
Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol (1994) 0.94
DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene (1999) 0.81
Lymphotoxin-alpha is an important autocrine factor for CD40 + interleukin-4-mediated B-cell activation in normal and atopic donors. Immunology (1998) 0.77
Protein synthesis inhibition is not a requisite for puromycin- and cycloheximide-induced c-myc mRNA superinduction. Anticancer Res (1994) 0.77
DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature (1984) 27.05
Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature (1999) 23.62
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell (1977) 6.22
A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J (1988) 3.69
Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature (1979) 3.43
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol (1989) 2.98
Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol (1985) 2.82
EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 2.79
Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. EMBO J (1984) 2.77
Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer (2000) 2.59
Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol (2000) 2.48
Pathways of activation of the Epstein-Barr virus productive cycle. J Virol (1991) 2.42
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology (1987) 2.32
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene (1991) 2.25
Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci U S A (1978) 2.22
Homologous upstream sequences near Epstein-Barr virus promoters. Proc Natl Acad Sci U S A (1983) 1.98
Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol (1990) 1.97
Sequence analysis of Raji Epstein-Barr virus DNA. Virology (1988) 1.95
Retracted Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (1989) 1.94
The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol (1999) 1.81
Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology (1990) 1.78
Interferon, double-stranded RNA and RNA degradation. Fractionation of the endonucleaseINT system into two macromolecular components; role of a small molecule in nuclease activation. Biochem Biophys Res Commun (1978) 1.70
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology (2011) 1.70
Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol (2000) 1.64
Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector. J Virol (1987) 1.61
Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol (1994) 1.60
The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol (1989) 1.59
Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol (2000) 1.57
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
Analysis of phosphorylation of protein synthesis initiation factor eIF-2 by two-dimensional gel electrophoresis. Eur J Biochem (1978) 1.54
Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J (1996) 1.53
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 1.52
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol (1997) 1.49
Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA. J Virol (1987) 1.45
Diving practices of scuba divers with asthma. BMJ (1990) 1.44
The role of polyamines in cell-free protein synthesis in the wheat-germ system. Eur J Biochem (1977) 1.43
Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol (1996) 1.41
Retracted High rate of human papillomavirus type 16 infection in cytologically normal cervices. Lancet (1989) 1.38
Chromatin structure of Epstein-Barr virus. J Gen Virol (1985) 1.37
Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol (2001) 1.34
DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J (1995) 1.33
DNA sequence analysis of the EcoRI Dhet fragment of B95-8 Epstein-Barr virus containing the terminal repeat sequences. Mol Biol Med (1983) 1.31
Prevalence of human papillomavirus type 16 DNA in cervical carcinoma samples in East Anglia. Int J Cancer (1985) 1.31
Interferon, double-stranded RNA, and RNA degradation. Isolation of homogeneous pppA(2'p5'A)n-1 synthetase from Ehrlich ascites tumor cells. J Biol Chem (1980) 1.30
Strain variation in Epstein-Barr virus immediate early genes. Virology (1993) 1.23
Unrearranged immunoglobulin variable region genes have a functional promoter. Nucleic Acids Res (1982) 1.23
Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J (1995) 1.23
Sequence analysis of the 17,166 base-pair EcoRI fragment C of B95-8 Epstein-Barr virus. Mol Biol Med (1983) 1.22
c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci U S A (1996) 1.20
Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol (2007) 1.18
Epstein-Barr virus SM protein. Virology (1994) 1.18
Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol (1996) 1.16
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res (2000) 1.14
Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. Biochem Biophys Res Commun (1995) 1.14
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol (1995) 1.12
Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J Virol (2001) 1.12
Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene (1996) 1.11
Cell growth effects of Epstein-Barr virus leader protein. J Gen Virol (1992) 1.09
Epstein-Barr virus transcription factors. Cell Growth Differ (1992) 1.09
Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol (1995) 1.09
Extracts of interferon-treated cells can inhibit reticulocyte lysate protein synthesis. Biochem Biophys Res Commun (1977) 1.08
Neoplastic transformation by Notch is independent of transcriptional activation by RBP-J signalling. Oncogene (2000) 1.06
Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol (1998) 1.05
Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol (1999) 1.04
A baculovirus (Bombyx mori nuclear polyhedrosis virus) repeat element functions as a powerful constitutive enhancer in transfected insect cells. J Biol Chem (1997) 1.03
Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J (2008) 1.02
Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers. Intervirology (1995) 1.02
Retraction: human papillomavirus subtype 16b. Lancet (1990) 1.00
Epstein-Barr virus gene expression in oral hairy leukoplakia. Virology (1993) 0.99
Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression. J Virol (1992) 0.99
Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. J Gen Virol (1995) 0.97
Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection. Thorax (1997) 0.96
Mutational analysis of the J recombination signal sequence binding protein (RBP-J)/Epstein-Barr virus nuclear antigen 2 (EBNA2) and RBP-J/Notch interaction. Eur J Biochem (2001) 0.95
Coding content and expression of the EBV B95-8 genome in the region from base 62,248 to base 82,920. Virology (1986) 0.94
Variant chromatin structure of the oriP region of Epstein-Barr virus and regulation of EBER1 expression by upstream sequences and oriP. J Virol (2001) 0.91
Characterization of hemopoietic cell populations from human cord blood expressing c-kit. Exp Hematol (1993) 0.91
Use of flow cytometry to rapidly optimize the transfection of animal cells. Biotechniques (2000) 0.91
Expression of Epstein-Barr virus nuclear antigen-2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21. Eur J Immunol (1995) 0.90
Differential splicing of Epstein-Barr virus immediate-early RNA. J Virol (1992) 0.90
Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology (1995) 0.90
Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet (1989) 0.90
Hebbian mechanisms help explain development of multisensory integration in the superior colliculus: a neural network model. Biol Cybern (2012) 0.89
Application of a generalized random effects regression model for cluster-correlated longitudinal data to a school-based smoking prevention trial. Am J Epidemiol (2000) 0.89
Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines. Virology (1994) 0.88
The Epstein-Barr virus nuclear antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphoma cell lines. Biol Chem (1999) 0.87
Biological activities of p53 mutants in Burkitt's lymphoma cells. J Gen Virol (1993) 0.87
A novel deletion within the upstream regulatory region of episomal human papillomavirus type 16. J Gen Virol (1989) 0.85
E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br J Cancer (2002) 0.84
p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer (2001) 0.84
Analysis of CHK2 in vulval neoplasia. Br J Cancer (2002) 0.84
Serum protein changes in cattle infected with Trypanosoma vivax. Trans R Soc Trop Med Hyg (1975) 0.82
Minimal domain requirement for cation transport by the potassium-dependent Na/Ca-K exchanger. Comparison with an NCKX paralog from Caenorhabditis elegans. J Biol Chem (2000) 0.82
Cell cycle arrest following exposure of EBV-immortalised B-cells to gamma irradiation correlates with inhibition of cdk2 activity. FEBS Lett (1998) 0.82
A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers. Gene Ther (1997) 0.81
DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene (1999) 0.81